Healthcare | Wed Mar 18, 2015 | 5:08am EDT
BRIEF-Sangui Biotech International says series of preclinical trials concluded successfully
March 18 Sangui Biotech International Inc  :
* Series of preclinical trials concluded successfully
* Research team including SanguiBioTech GmbH has now concluded a series of preclinical trials at Giessen University dedicated to indication of septic shock  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)
Next In Healthcare
* Provectus Biopharmaceuticals terminates Peter Culpepper as interim CEO and COO  Source text for Eikon:  Further company coverage:
MORE FROM REUTERS
From Around the Web Promoted by Taboola
Trending Stories
Reuters News Agency | Brand Attribution Guidelines
Reuters is the news and media division of Thomson Reuters . Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products:
